ADA: Improve insulin access, affordability

Thursday, May 31, 2018

ARLINGTON, Va. – The American Diabetes Association on May 24 released a public policy statement outlining both long- and short-term recommendations for improving insulin access and affordability. The recommendations in “ADA Public Policy Statement: Insulin Access and Affordability” include increasing transparency across the entire insulin supply chain; streamlining the approval process for biosimilar insulins; lowering or removing patient cost-sharing for insulin; and increasing access to healthcare coverage for all people with diabetes. The statement follows a white paper, “Insulin Access and Affordability Working Group: Conclusions and Recommendations,” published on May 8 in Diabetes Care. The ADA’s Chief Scientific, Medical & Mission Officer William T. Cefalu, M.D., also testified that day before the U.S. Senate’s Special Committee on Aging to share the findings and conclusions in the white paper. A recent survey by the ADA confirmed that individuals who face high out-of-pocket costs for insulin are not adhering to their diabetes care plan by either rationing or forgoing insulin doses to reduce costs. The statement is the latest milestone in the ADA’s Make Insulin Affordable strategic initiative, which launched in November 2016 and includes a petition that has been signed by nearly 350,000 individuals.